Literature DB >> 23928059

Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma.

M Imran Aslam1, Simone Hettmer, Jinu Abraham, Dorian Latocha, Anuradha Soundararajan, Elaine T Huang, Martin W Goros, Joel E Michalek, Shuyu Wang, Atiya Mansoor, Brian J Druker, Amy J Wagers, Jeffrey W Tyner, Charles Keller.   

Abstract

UNLABELLED: Since the advent of tyrosine kinase inhibitors as targeted therapies in cancer, several receptor tyrosine kinases (RTK) have been identified as operationally important for disease progression. Rhabdomyosarcoma (RMS) is a malignancy in need of new treatment options; therefore, better understanding of the heterogeneity of RTKs would advance this goal. Here, alveolar RMS (aRMS) tumor cells derived from a transgenic mouse model expressing two such RTKs, platelet-derived growth factor (PDGFR)α and insulin-like growth factor (IGF)-1R, were investigated by fluorescence-activated cell sorting (FACS). Sorted subpopulations that were positive or negative for PDGFRα and IGF-1R dynamically altered their cell surface RTK expression profiles as early as the first cell division. Interestingly, a difference in total PDGFRα expression and nuclear IGF-1R expression was conserved in populations. Nuclear IGF-1R expression was greater than cytoplasmic IGF-1R in cells with initially high cell surface IGF-1R, and cells with high nuclear IGF-1R established tumors more efficiently in vivo. RNA interference-mediated silencing of IGF-1R in the subpopulation of cells initially harboring higher cell surface and total IGF-1R resulted in significantly reduced anchorage-independent colony formation as compared with cells with initially lower cell surface and total IGF-1R expression. Finally, in accordance with the findings observed in murine aRMS, human aRMS also had robust expression of nuclear IGF-1R. IMPLICATIONS: RTK expression status and subcellular localization dynamics are important considerations for personalized medicine. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23928059      PMCID: PMC3834004          DOI: 10.1158/1541-7786.MCR-12-0598

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  34 in total

1.  Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Mol Biol Cell       Date:  2007-01-10       Impact factor: 4.138

2.  Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain.

Authors:  S Pablo Sardi; Joshua Murtie; Samir Koirala; Brooke A Patten; Gabriel Corfas
Journal:  Cell       Date:  2006-10-06       Impact factor: 41.582

Review 3.  Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function.

Authors:  Sanchita Mukherjee; Mathewos Tessema; Angela Wandinger-Ness
Journal:  Circ Res       Date:  2006-03-31       Impact factor: 17.367

Review 4.  Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling.

Authors:  Christine Le Roy; Jeffrey L Wrana
Journal:  Nat Rev Mol Cell Biol       Date:  2005-02       Impact factor: 94.444

Review 5.  Rhabdomyosarcoma. Biology and treatment.

Authors:  A S Pappo; D N Shapiro; W M Crist
Journal:  Pediatr Clin North Am       Date:  1997-08       Impact factor: 3.278

6.  Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.

Authors:  Charles Keller; Benjamin R Arenkiel; Cheryl M Coffin; Nabeel El-Bardeesy; Ronald A DePinho; Mario R Capecchi
Journal:  Genes Dev       Date:  2004-10-15       Impact factor: 11.361

7.  Platelet-derived growth factor receptor-mediated signal transduction from endosomes.

Authors:  Yi Wang; Steven D Pennock; Xinmei Chen; Andrius Kazlauskas; Zhixiang Wang
Journal:  J Biol Chem       Date:  2003-12-02       Impact factor: 5.157

8.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

9.  Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells.

Authors:  Lubna Patrawala; Tammy Calhoun-Davis; Robin Schneider-Broussard; Dean G Tang
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

10.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

View more
  15 in total

Review 1.  Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Authors:  Venkatesh P Kashi; Mark E Hatley; Rene L Galindo
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

Review 2.  Targeting protein kinases to reverse multidrug resistance in sarcoma.

Authors:  Hua Chen; Jacson Shen; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2015-12-08       Impact factor: 12.111

3.  Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage.

Authors:  Tamara Aleksic; Nicki Gray; Xiaoning Wu; Guillaume Rieunier; Eliot Osher; Jack Mills; Clare Verrill; Richard J Bryant; Cheng Han; Kathryn Hutchinson; Adam G Lambert; Rajeev Kumar; Freddie C Hamdy; Ulrike Weyer-Czernilofsky; Michael P Sanderson; Thomas Bogenrieder; Stephen Taylor; Valentine M Macaulay
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

4.  Nuclearly translocated insulin-like growth factor 1 receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2 expression via Brg1 chromatin remodeling protein.

Authors:  Dudi Warsito; Yingbo Lin; Ann-Christin Gnirck; Bita Sehat; Olle Larsson
Journal:  Oncotarget       Date:  2016-07-05

5.  SUMO-modified insulin-like growth factor 1 receptor (IGF-1R) increases cell cycle progression and cell proliferation.

Authors:  Yingbo Lin; Hongyu Liu; Ahmed Waraky; Felix Haglund; Prasoon Agarwal; Helena Jernberg-Wiklund; Dudi Warsito; Olle Larsson
Journal:  J Cell Physiol       Date:  2017-04-25       Impact factor: 6.384

Review 6.  New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations.

Authors:  Joseph A M J L Janssen
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

Review 7.  Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.

Authors:  Hui Hua; Qingbin Kong; Jie Yin; Jin Zhang; Yangfu Jiang
Journal:  J Hematol Oncol       Date:  2020-06-03       Impact factor: 17.388

Review 8.  New insights into signalling-pathway alterations in rhabdomyosarcoma.

Authors:  B Zhu; J K Davie
Journal:  Br J Cancer       Date:  2014-09-11       Impact factor: 7.640

9.  Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.

Authors:  Francesca Megiorni; Heather P McDowell; Simona Camero; Olga Mannarino; Simona Ceccarelli; Milena Paiano; Paul D Losty; Barry Pizer; Rajeev Shukla; Antonio Pizzuti; Anna Clerico; Carlo Dominici
Journal:  J Exp Clin Cancer Res       Date:  2015-10-06

10.  An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma.

Authors:  Sorah Yoon; Xiwei Wu; Brian Armstrong; Nagy Habib; John J Rossi
Journal:  Mol Ther Nucleic Acids       Date:  2018-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.